Below are the most recent publications written about "Immunogenicity, Vaccine" by people in Profiles.
-
Hannawi S, Wu XH, Villalobos RE, Burhan E, Lallaine Borra MD, Gupta RK, Aquitania GP, Ang BWC, Mae A Zabat G, Roa CC, Zoleta-De Jesus L, Yu DD, Wang M, Wu Y, Song WJ, Ying B, Qin CF. Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial. Med. 2024 Oct 11; 5(10):1282-1292.e3.
-
Alugupalli KR. A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines. Front Immunol. 2024; 15:1383476.
-
Alugupalli KR. TLR4 Ligands in Typhoid Vi Polysaccharide Subunit Vaccines Contribute to Immunogenicity. Immunohorizons. 2024 01 01; 8(1):29-34.
-
Shannon CP, Blimkie TM, Ben-Othman R, Gladish N, Amenyogbe N, Drissler S, Edgar RD, Chan Q, Krajden M, Foster LJ, Kobor MS, Mohn WW, Brinkman RR, Le Cao KA, Scheuermann RH, Tebbutt SJ, Hancock REW, Koff WC, Kollmann TR, Sadarangani M, Lee AH. Multi-Omic Data Integration Allows Baseline Immune Signatures to Predict Hepatitis B Vaccine Response in a Small Cohort. Front Immunol. 2020; 11:578801.
-
Kandeil A, Gomaa MR, El Taweel A, Mostafa A, Shehata M, Kayed AE, Kutkat O, Moatasim Y, Mahmoud SH, Kamel MN, Shama NMA, El Sayes M, El-Shesheny R, Yassien MA, Webby RJ, Kayali G, Ali MA. Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2. PLoS One. 2020; 15(10):e0241471.
-
Laczk? D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Casta?o D, Amanat F, Muramatsu H, Oguin TH, Ojha A, Zhang L, Mu Z, Parks R, Manzoni TB, Roper B, Strohmeier S, Tomb?cz I, Arwood L, Nachbagauer R, Karik? K, Greenhouse J, Pessaint L, Porto M, Putman-Taylor T, Strasbaugh A, Campbell TA, Lin PJC, Tam YK, Sempowski GD, Farzan M, Choe H, Saunders KO, Haynes BF, Andersen H, Eisenlohr LC, Weissman D, Krammer F, Bates P, Allman D, Locci M, Pardi N. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity. 2020 10 13; 53(4):724-732.e7.
-
Li SC, Kabeer MH. Autologous Splenocyte Reinfusion Improves Antibody-Mediated Immune Response to the 23-Valent Pneumococcal Polysaccharide-Based Vaccine in Splenectomized Mice. Biomolecules. 2020 05 01; 10(5).
-
Pollack KE, Meneveau MO, Melssen MM, Lynch KT, Koeppel AF, Young SJ, Turner S, Kumar P, Sol-Church K, Mauldin IS, Slingluff CL. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J Immunother Cancer. 2020 04; 8(1).
-
George PJ, Hess JA, Jain S, Patton JB, Zhan T, Tricoche N, Zhan B, Bottazzi ME, Hotez PJ, Abraham D, Lustigman S. Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans. PLoS Negl Trop Dis. 2019 09; 13(9):e0007730.
-
Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer. 2019 04 23; 7(1):104.